[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Tokuchi Y, Kamachi M, Harada M, Hasegawa M, Mishina T, Yamashiro K, Suzuki H, Isobe H: Synchronous triple lung cancers after treatment for non-Hodgkin's lymphoma: metachronous quadruple cancers. Intern Med; 2003 Oct;42(10):1031-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous triple lung cancers after treatment for non-Hodgkin's lymphoma: metachronous quadruple cancers.
  • After chemotherapy and radiotherapy for non-Hodgkin's lymphoma during a one-year period, a 66-year-old man developed synchronous triple lung cancers in both lungs.
  • Although he received repeated chemotherapy for lung cancer, the patient died of hepatic failure due to multiple liver metastases.
  • Autopsy revealed disseminated metastasis of the large cell carcinoma with neuroendocrine morphology throughout the entire body, but no recurrence of malignant lymphoma or squamous cell carcinoma was found.
  • To our knowledge, this is the first report of triple lung cancers occurring after treatment for malignant lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Large Cell / etiology. Carcinoma, Squamous Cell / etiology. Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Lung Neoplasms / etiology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasms, Multiple Primary / etiology. Neoplasms, Second Primary / etiology. Prednisone / adverse effects. Radiotherapy / adverse effects. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14606721.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Otrock ZK, Hatoum HA, Uthman IW, Taher AT, Saab S, Shamseddine AI: Non-Hodgkin's lymphoma in a woman with adult-onset Still's disease: a case report. J Med Case Rep; 2008;2:73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in a woman with adult-onset Still's disease: a case report.
  • Searching the medical literature using the MEDLINE database from January 1966 through November 2007 we could only find two reported cases of adult onset Still's disease that had progressed to lymphoma.
  • CASE PRESENTATION: We describe a woman who was diagnosed with adult onset Still's disease and developed lymphoma 10 months after the onset of her symptoms.
  • On physical examination she was found to have several enlarged anterior cervical lymph nodes and left posterior auricular lymph nodes all of which were non-tender, immobile and rubbery.
  • Work up revealed malignant lymphoma.
  • She was treated with chemotherapy and was doing well until she presented with abdominal pain.
  • Work up revealed a cirrhotic liver and ascites.
  • She then passed away from hepatorenal syndrome 13 years after the diagnosis of lymphoma.
  • CONCLUSION: Although the association between adult onset Still's disease and lymphoma has been rarely reported, careful screening for this malignancy in patients suspected to have adult onset Still's disease is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 1989 Mar;16(3):349-54 [2724252.001]
  • [Cites] J Rheumatol. 1987 Dec;14(6):1139-46 [3325642.001]
  • [Cites] J Rheumatol. 1988 Jun;15(6):981-3 [3418650.001]
  • [Cites] Medicine (Baltimore). 1973 Sep;52(5):431-44 [4725963.001]
  • [Cites] Ann Rheum Dis. 1971 Mar;30(2):121-33 [5315135.001]
  • [Cites] Br J Rheumatol. 1995 Oct;34(10):984-8 [7582709.001]
  • [Cites] Medicine (Baltimore). 1991 Mar;70(2):118-36 [2005777.001]
  • [Cites] Lupus. 2000;9(6):468-70 [10981654.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):197-202 [12232573.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2004 Oct;18(5):663-76 [15454125.001]
  • [Cites] J Rheumatol. 1992 Mar;19(3):424-30 [1578458.001]
  • [Cites] Baillieres Clin Rheumatol. 1991 Aug;5(2):263-75 [1756584.001]
  • [Cites] J Rheumatol. 1991 Sep;18(9):1418-23 [1757949.001]
  • [Cites] J Rheumatol. 1993 Oct;20(10):1788-92 [8295197.001]
  • (PMID = 18325097.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2270857
  •  go-up   go-down


3. Kang KM, Chung WC, Lee KM, Hur SE, Nah JM, Kim GH, Back JY, Kim SK, Yang JM, Choi HJ: [A case of primary hepatic lymphoma mimicking hepatitis]. Korean J Hepatol; 2005 Sep;11(3):284-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary hepatic lymphoma mimicking hepatitis].
  • We report here on a case of non-Hodgkin's lymphoma in which liver involvement was the predominant clinical manifestation.
  • The abdominal CT scan showed only diffuse hepatosplenomegaly and uneven contrast enhancement of the spleen without any definite mass of the liver and spleen.
  • US-guided aspiration biopsy of liver and the histologic examination confirmed a diagnosis of non-Hodgkin's lymphoma, the diffuse large B cell type.
  • Bone marrow biopsy showed the infiltration of malignant lymphoma cells.
  • PET-CT showed an increased FDG uptake of the liver, spleen and long bones.
  • The patient was treated with combination regimen of cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy.
  • Even in the absence of a mass lesion or lymphadenopathy, primary hepatic or hepatosplenic lymphoma should be considered in differential diagnosis of hepatitis or liver cirrhosis, especially for patients with diffuse hepatosplenomegaly and markedly elevated LDH.
  • [MeSH-major] Hepatitis / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177555.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


Advertisement
4. Mori M, Niitsu N, Takagi T, Tomiyama J, Matsue T, Nakagawa Y, Okamoto R: Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma; 2001 Apr;41(3-4):359-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma.
  • While CHOP therapy is effective for malignant lymphoma, the optimum schedule for elderly patients remains controversial.
  • The present study investigated the usefulness of reduced-dose CHOP therapy for elderly patients.
  • Previously untreated patients aged 65 years or older with intermediate to high-grade non-Hodgkin's lymphoma were given up to 6 courses of reduced-dose CHOP therapy at 3-week intervals.
  • Fifty-seven patients were evaluable and the scheduled therapy was completed in 37.
  • Grade 3 cardiac plus renal failure, grade 3 peritonitis due to small bowel perforation, and grade 3 liver dysfunction occurred in 1 patient each.
  • In conclusion, it seems that in the elderly patients with non-Hodgkin's lymphoma, response to reduced-dose ((5/6) dose) CHOP therapy is comparable to that for standard CHOP in younger adults, mainly because of improved dose-intensity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Age Factors. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Female. Humans. Male. Pilot Projects. Prednisone / administration & dosage. Prednisone / toxicity. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / toxicity

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378549.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Lee SH, Kim HJ, Mun JS, Oh HC, Lee HW, Choi CH, Kim JW, Do JH, Kim JG, Chang SK, Kim MK: A case of primary hepatic Burkitt's lymphoma. Korean J Gastroenterol; 2008 Apr;51(4):259-64
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary hepatic Burkitt's lymphoma.
  • Burkitt's lymphoma is a rare disease that belongs to the aggressive non-Hodgkin's lymphoma.
  • Herein, we report a case of primary hepatic Burkitt's lymphoma.
  • Abdominal-Pelvis CT scan and abdominal MRI finding were compatible with malignant lymphoma.
  • Liver biopsy examination confirmed Burkitt's lymphoma.
  • Chemotherapy was administered every 3 weeks for fifteen cycles.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Diagnosis, Differential. Humans. Male. Methotrexate / therapeutic use. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516006.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Eidt S, Nebeling M, Pohl C, Siedek M: [Neoadjuvant chemotherapy of primary hepatic non-Hodgkin's lymphoma]. Med Klin (Munich); 2003 Feb 15;98(2):96-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy of primary hepatic non-Hodgkin's lymphoma].
  • [Transliterated title] Neoadjuvante Chemotherapie eines primären malignen Non-Hodgkin-Lymphoms der Leber.
  • BACKGROUND: Since primary malignant lymphomas of the liver represent a rare entity, no commonly accepted therapeutic strategy has been developed so far.
  • CASE STUDY: We report the case of a diffuse large-cell B-cell lymphoma of the liver in a 48-year-old female patient.
  • After neoadjuvant chemotherapy, the lymphoma was completely resected (R0).
  • A massive therapy-induced tumor regression was found histologically.
  • After six courses of adjuvant chemotherapy, the patient has been alive and well for more than 5 years and shows no evidence of tumor relapse.
  • CONCLUSION: This case documents the effect of systemic chemotherapy on lymphoma cells.
  • In many centers systemic chemotherapy is used as the only therapeutic regimen.
  • Neoadjuvant chemotherapy might, however, represent an important addition to the therapeutic strategies concerning unilocular primary hepatic lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Liver Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Hepatectomy. Humans. Immunohistochemistry. Liver / pathology. Middle Aged. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12601534.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Hsieh PY, Huang SI, Li DK, Mao TL, Sheu JC, Chen CH: Primary effusion lymphoma involving both pleural and abdominal cavities in a patient with hepatitis B virus-related liver cirrhosis. J Formos Med Assoc; 2007 Jun;106(6):504-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary effusion lymphoma involving both pleural and abdominal cavities in a patient with hepatitis B virus-related liver cirrhosis.
  • Primary effusion lymphoma (PEL) is an unusual form of non-Hodgkin's lymphoma, which is characterized by lymphomatous effusion in body cavities, but no associated mass lesions.
  • We describe a 54-year-old man with HIV-negative PEL, with a history of hepatitis B virus-related liver cirrhosis.
  • The genomic human herpesvirus-8 was detected in the lymphoma cells.
  • The patient received four cycles of chemotherapy of CHOP and Picibanil (OK-432) intraperitoneal administration.
  • Adefovir failed to halt the progressive liver failure after the development of YMDD mutant related to lamivudine.


8. Hsu PK, Hsu HS, Li AF, Wang LS, Huang BS, Huang MH, Hsu WH: Non-Hodgkin's lymphoma presenting as a large chest wall mass. Ann Thorac Surg; 2006 Apr;81(4):1214-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as a large chest wall mass.
  • BACKGROUND: Malignant lymphoma presenting as a solitary chest wall mass is not frequently seen.
  • The treatment for primary chest wall lymphoma remains unclear.
  • METHODS: From 1991 to 2004, of 157 patients with initial presentation of isolated chest wall mass, non-Hodgkin's lymphoma was diagnosed in 7 of them.
  • Four of these 7 patients had the chest wall lymphoma as the only site of disease.
  • The other 3 patients had other organ involvement including lung, bone, or liver.
  • The pathologic diagnoses were malignant lymphoma in 2 patients and diffuse large B-cell lymphoma in 5 patients.
  • Three patients with chest wall lymphoma as the only site of disease had tumor excision followed by adjuvant chemotherapy.
  • The other patient with chest wall lymphoma as the only site of disease, who had chemotherapy as the initial treatment, remained free of disease for 6 months after treatment.
  • The other 3 patients with other organ involvement who were managed with chemotherapy with or without radiotherapy died of disease after a mean survival of 20 months.
  • CONCLUSIONS: Malignant lymphoma presenting as a large chest wall mass is not common.
  • Although the primary treatment of choice for lymphoma with or without chest wall involvement is chemotherapy, surgery followed by adjuvant chemotherapy can provide satisfactory outcome for some patients in whom the chest wall lymphoma was the only site of disease.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse. Thoracic Neoplasms. Thoracic Wall

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Apr;81(4):1218-9 [16564246.001]
  • (PMID = 16564245.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 30
  •  go-up   go-down


9. Vera P, Ouvrier MJ, Hapdey S, Thillays M, Pesquet AS, Diologent B, Callonec F, Hitzel A, Edet-Sanson A, Ménard JF, Jardin F, Tilly H: Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging; 2007 Dec;34(12):1943-52
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?
  • PURPOSE: In patients with lymphoma, we investigated the impact of contrast-enhanced CT on PET attenuation correction in lesions and normal tissues, particularly when PET/CT was performed after chemotherapy.
  • METHODS: Fifty patients (51+/-18 years) with Hodgkin's disease (n=17) or non-Hodgkin lymphomas (n=33) were studied before and after chemotherapy.
  • HU(mean), SUV(max) and SUV(mean) were measured before and after chemotherapy in ten non-tumoural ROIs [aorta, femur, kidney, lung, iliopsoas muscle, occipital cortex, T12 vertebra, liver, spleen and inferior vena cava (IVC)] and in tumoural lymphadenopathies or malignant tissues (n=397 and 51 VOIs respectively before and after chemotherapy) using a 3D-thresholding method (identical threshold for PET- and PET+).
  • RESULTS: In the non-tumoural tissues, HU(mean) increased significantly in the CT+ compared with the CT- in the vessels and the highly vascularised organs, and slight increases were observed in the occipital cortex (+11%), the iliopsoas muscle (+6%) and the femur (+3%).
  • SUV(max) increased significantly in the PET+ compared with the PET- in the aorta (+14%), the liver (+10%), the spleen (+10%) and the IVC (+12%).
  • SUV(mean) increased significantly in the PET+ compared with the PET- in the aorta (+15%), the kidney (+13%), the liver (+11%), the spleen (10%) and the IVC (+12%).
  • In the lesions, HU(mean) was not significantly different before and after chemotherapy, whatever the normal region considered.
  • SUV(max) increased significantly after treatment in the T12 vertebra (+12%).
  • SUV(mean) increased significantly after treatment in the T12 vertebra (+13%) and in the liver (+12%).
  • HU(mean) increased significantly in the CT+ compared with the CT- in the lesions (+55%) before chemotherapy.
  • SUV(max) and SUV(mean) increased significantly in the PET+ compared with the PET- in the lesions (+4%) only before chemotherapy.
  • No significant difference was seen in measurements (HU(mean), SUV(max) and SUV(mean)) after chemotherapy.
  • CONCLUSION: Our study demonstrates that use of enhanced CT for attenuation correction has a negligible effect on quantification at staging and after chemotherapy.
  • A "single-shot" enhanced PET/CT may thus be performed in the evaluation of patients with lymphoma at staging, during treatment and at follow-up.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Contrast Media. Lymphoma / diagnostic imaging. Lymphoma / drug therapy. Positron-Emission Tomography / methods. Subtraction Technique. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1167-75 [15909196.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):W498-502 [17056880.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):922-7 [12111133.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1129-36 [12215549.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Clin Nucl Med. 2000 Nov;25(11):905-10 [11079589.001]
  • [Cites] J Nucl Med. 2005 Mar;46(3):429-35 [15750155.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):325-9 [14647988.001]
  • [Cites] Q J Nucl Med. 2002 Mar;46(1):24-34 [12072843.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):983-95 [15937310.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1326-34 [16883013.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10 ):1643-8 [17015900.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):308-19 [16423932.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1555-60 [12438054.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2505-9 [9406703.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] J Nucl Med. 2004 May;45(5):784-8 [15136627.001]
  • [Cites] Br J Radiol. 2004 Aug;77(920):662-5 [15326044.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):470-6 [16513616.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):22-8 [14574514.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):283-91 [15695788.001]
  • [Cites] Radiology. 2002 Nov;225(2):575-81 [12409597.001]
  • [Cites] Radiology. 2003 Jun;227(3):817-24 [12773683.001]
  • (PMID = 17694309.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  •  go-up   go-down


10. Civardi G, Vallisa D, Bertè R, Lazzaro A, Moroni CF, Cavanna L: Focal liver lesions in non-Hodgkin's lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection. Eur J Cancer; 2002 Dec;38(18):2382-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal liver lesions in non-Hodgkin's lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection.
  • Imaging techniques like ultrasonography (US) or computed tomography (CT) allow full liver scanning and the accurate detection of focal lesions of the liver parenchyma.
  • The occurrence of such lesions in concomitance with non-Hodgkin's lymphoma (NHL), both at the onset of the disease and during follow-up, is of great significance, because it affects staging, prognosis and therapeutic choices.
  • Moreover, the occurrence of focal liver lesions in the setting of a lymphoma is generally considered to be a marker of liver involvement.
  • Nonetheless, data on the prevalence and clinical significance of focal liver lesions occurring in these clinical conditions are limited.
  • Therefore, we retrospectively evaluated the prevalence, nature and clinical significance of focal liver lesions diagnosed by imaging techniques (US and CT) in 414 consecutive NHL patients.
  • The nature of the lesions was established either by US-guided biopsy or by evaluation of the response to chemotherapy for the underlying disease and confirmed by clinical and US follow-up.
  • We detected 129 focal liver lesions (76 at onset and 53 during the follow-up).
  • At onset, only 39% of the detected lesions were due to lymphoma and 58% were benign.
  • Conversely, 74% of the liver lesions detected during the follow-up were due to NHL while 15% to a malignancy other than NHL.
  • All HCC cases occurred in HCV-positive patients with chronic liver disease.
  • We concluded that the focal liver lesions detected at onset in NHL patients are frequently benign and unrelated to the underlying disease.
  • Conversely, most focal liver lesions detected during the follow-up period are malignant and the possibility of HCC occurrence in HCV-positive patients should always be considered.
  • [MeSH-major] Hepatitis C, Chronic / pathology. Liver Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Biopsy, Needle / methods. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / ultrasonography. Cysts / pathology. Cysts / radiography. Cysts / ultrasonography. Female. Follow-Up Studies. Hemangioma / pathology. Hemangioma / radiography. Hemangioma / ultrasonography. Humans. Liver Diseases / pathology. Liver Diseases / radiography. Liver Diseases / ultrasonography. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12460782.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA: Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation; 2006 Aug 15;82(3):375-81
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
  • BACKGROUND: Recommended first-line treatment for posttransplant lymphoproliferative disorder (PTLD) is reduction in immunosuppressive therapy, irrespective of histopathological type.
  • Second-line treatment with chemotherapy is generally reserved for tumors that fail to respond to reduced immunosuppression.
  • In view of the similarities between monomorphic PTLD and non-Hodgkin's lymphoma in the general population, our policy is to treat monomorphic PTLD with anthracycline-based chemotherapy as first-line treatment.
  • METHODS: A retrospective single-center analysis of 18 adults who developed PTLD following liver or kidney transplantation was undertaken, with particular emphasis on tumor histology, treatment received, and clinical outcome.
  • RESULTS: Of the 18 patients with PTLD, 13 had high-grade malignant lymphoma on diagnostic biopsy and received anthracycline-based chemotherapy and reduction in immunosuppression as first-line therapy.
  • Nine (69%) of the 13 patients achieved complete remission and eight (62%) remained in complete remission five years after diagnosis.
  • There was no graft loss from rejection or drug toxicity.
  • Four (22%) patients had polymorphic PTLD on diagnostic biopsy (of which two were re-classified as monomorphic) and one had a low-grade malignant lymphoma.
  • All five patients were treated by reduction in immunosuppression without chemotherapy and were in complete remission at a median of two years after diagnosis.
  • Overall, complete remission was seen in 14 out of 18 patients (78%) at one year following diagnosis.
  • CONCLUSION: The use of anthracycline-based chemotherapy and reduction of immunosuppression as first-line treatment in adults with monomorphic PTLD is well tolerated and achieves sustained complete remission in around 70% of patients with a low risk of graft loss.
  • [MeSH-major] Anthracyclines / therapeutic use. Kidney Transplantation. Lymphoma / drug therapy. Lymphoma / pathology. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906036.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


12. O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL: A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res; 2000 Sep-Oct;20(5C):3647-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
  • BACKGROUND: Prior clinical trials proved that all histologic grades of chemotherapy-resistant B-cell non-Hodgkin's lymphoma (NHL) could respond to radio-immunotherapy (RIT) with 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1.
  • METHODS: Lym-1 is a mouse monoclonal antibody that preferentially targets malignant B-lymphocytes.
  • 90Y has beta emissions suitable for therapy but no gamma emissions, therefore, 111In-2IT-BAD-Lym-1 is used for imaging.
  • The macrocyclic chelator, DOTA, bound 90Y tightly to form a stable drug.
  • Patients with chemotherapy-resistant NHL received 90Y-2IT-BAD-Lym-1 at administered doses of: 0.185, 0.278, or 0.370 GBq/m2.
  • No significant non-hematologic toxicity occurred.
  • Human anti-mouse antibody (HAMA) developed in 3/8 patients.
  • The mean radiation dose to the 33 imaged tumors was 7.0 Gy/GBq.
  • Lung, kidney and liver received mean radiation doses of 1.3, 2.4, and 6.4 Gy/GBq, respectively from 90Y-2IT-BAD-Lym-1.
  • In this Phase I study, 5/8 patients that failed prior chemotherapy had a partial response or stabilization of NHL after RIT.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / adverse effects. Yttrium Radioisotopes / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268433.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA47829
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 2IT-BAD-Lym-1 monoclonal antibody; 0 / Antibodies, Heterophile; 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes
  •  go-up   go-down


13. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data.
  • Second neoplasm developed in 32 cases (4.8%).
  • Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia.
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Cameron AM, Truty J, Truell J, Lassman C, Zimmerman MA, Kelly BS Jr, Farmer DG, Hiatt JR, Ghobrial R, Busuttil RW: Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy. Transplantation; 2005 Oct 15;80(7):993-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy.
  • Systemic lymphomas may involve the liver but rarely cause fulminant hepatic failure (FHF).
  • Acute liver failure from primary hepatic lymphoma (PHL) is even less common with most patients succumbing to the sequelae of FHF before the correct diagnosis is made.
  • We report a patient who underwent successful orthotopic liver transplant (OLT) and chemotherapy for FHF secondary to PHL.
  • This previously-well male developed profound coagulopathy and encephalopathy 6 weeks after the onset of jaundice and fatigue.
  • Workup failed to reveal the underlying cause of his liver failure and the patient soon required urgent OLT.
  • Pathologic evaluation of his explanted liver revealed a malignant T-cell rich, large B-cell non-Hodgkin's lymphoma with widespread hepatocellular necrosis.
  • The patient made an excellent clinical recovery and is undergoing CHOP-Rituxan chemotherapy.
  • This scenario demonstrates that lymphoma should be considered in the differential diagnosis of FHF without clear etiology because of the potential for intervention with transplant and chemotherapy.
  • [MeSH-major] Liver Failure, Acute / surgery. Liver Neoplasms / complications. Liver Transplantation. Lymphoma, B-Cell / complications
  • [MeSH-minor] Combined Modality Therapy. Humans. Liver / pathology. Male. Middle Aged. Treatment Outcome


15. Thompson DR, Faust TW, Stone MJ, Polter DE: Hepatic failure as the presenting manifestation of malignant lymphoma. Clin Lymphoma; 2001 Sep;2(2):123-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic failure as the presenting manifestation of malignant lymphoma.
  • Liver transplantation may be lifesaving.
  • Hepatic invasion by malignant lymphoma is a rare cause of liver failure, but one that is potentially responsive to treatment.
  • Lymphoma (non-Hodgkin's or Hodgkin's) should be included in the differential diagnosis of fulminant hepatic failure so that liver transplantation is avoided and appropriate therapy can be instituted.
  • The findings and clinical course of 4 patients with liver failure due to hepatic lymphoma, who were referred to our institution for liver transplant evaluation, are presented and discussed.
  • Review of the literature revealed less than 40 cases of lymphoma presenting as fulminant hepatic failure.
  • The diagnosis of malignant lymphoma may be difficult.
  • Early liver biopsy with adequate tissue and immunologic studies is mandatory for diagnosis.
  • This condition may be reversible and may respond to chemotherapy if the diagnosis is made prior to multiorgan system failure.
  • The presence of malignant lymphoma is considered a contraindication to liver transplantation, although firm data are lacking.
  • [MeSH-major] Liver Failure / diagnosis. Lymphoma / diagnosis. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Humans. Immunohistochemistry. Liver Transplantation. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707855.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Di Cosimo S, Ferretti G, Partenzi A, Manicone AM, D'Aprile M: Gastric stump lymphoma five years after distal gastrectomy. Leuk Lymphoma; 2003 Feb;44(2):365-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric stump lymphoma five years after distal gastrectomy.
  • We report the case of a 77-year-old man who developed low grade B cell non-Hodgkin's lymphoma of the gastric stump 5 years after undergoing a distal gastrectomy for benign gastric ulcer.
  • Lymphoma occurring in the post-operative stomach would appear to be very rare, with only 14 previously recorded cases.
  • The median period of lymphoma onset after ulcer surgery is about 20 years (range 9-43 years) and gastric remnants of lymphoma are generally diagnosed in low stage, when surgery is possible and makes the prognosis good.
  • The patient developed lymphoma within 5 years of the ulcer surgery, thus, earlier than generally reported in literature; he presented with massive regional and extra-regional nodes involvement and liver metastases and he poorly responded to antiblastic chemotherapy.
  • The pathogenetic role of Helicobacter pylori (HP) infection and the possibility of malignant lymphoma developing in the gastric stump are discussed.
  • [MeSH-major] Gastrectomy / adverse effects. Lymphoma, B-Cell / etiology. Stomach Neoplasms / etiology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Stomach Ulcer / complications. Stomach Ulcer / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12688360.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


17. Ozden I, Yavuz E, Acarli K, Karabulut L, Yöney E, Cevikbaş U, Alper A: Primary lymphoma of the liver: report of a case. Surg Today; 2000;30(4):376-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the liver: report of a case.
  • We describe herein a female patient with non-Hodgkin's lymphoma of the liver and present a review of the related literature.
  • The patient was referred with the diagnosis of malignant hemangiopericytoma (with an open biopsy).
  • Histopathological and immunohistochemical examinations revealed non-Hodgkin's lymphoma of B-cell type.
  • These findings established the diagnosis of primary hepatic lymphoma.
  • The best treatment results have been obtained by a resection followed by chemotherapy when feasible.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10795873.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


18. Andersson PO, Brune M, Ekman T: Remission inversion and no transplant-related mortality--a single centre experience of autologous stem cell transplantation in malignant lymphoma. Acta Oncol; 2000;39(7):849-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission inversion and no transplant-related mortality--a single centre experience of autologous stem cell transplantation in malignant lymphoma.
  • Between 1989 and 1998 93 patients with malignant lymphoma were treated, in our centre, with high-dose chemotherapy and autologous stem cell transplantation.
  • Diagnosis according to the REAL-classification were: 38 patients with high-grade lymphoma (diffuse large B-cell lymphoma (DLCL) (n = 26), anaplastic T-cell (n = 5), lymfoblastic (n = 3) and others (n = 4)), 31 patients with low-grade lymphoma (follicular (n = 18), mantle cell (n = 4), B-CLL (n = 3) and others (n = 6)) and, finally, 24 patients with Hodgkin's disease.
  • One patient died 11 months post-transplant in unexplained liver failure and all other causes of death were related to relapse of lymphoma.
  • (c) Hodgkin's lymphoma (24 patients, 5-year probability) OS 65%, PFS 55%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma / mortality. Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11145444.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


19. Goh SG, Chuah KL, Tan PH: Intravascular lymphomatosis of the lung and liver following eyelid lymphoma in a Chinese man and review of primary pulmonary intravascular lymphomatosis. Pathology; 2002 Feb;34(1):82-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular lymphomatosis of the lung and liver following eyelid lymphoma in a Chinese man and review of primary pulmonary intravascular lymphomatosis.
  • Intravascular lymphomatosis (IVL) is characterised by an almost exclusive intravascular proliferation of malignant lymphoid cells, with the diagnosis often made only when the illness is in its terminal phase or at autopsy.
  • We detail a case of IVL affecting the lung and liver of a 49-year-old Chinese man presenting primarily with lung symptoms and incidental findings of abnormal serum transaminase levels, the ante-mortem diagnosis being established on transbronchial lung biopsy and percutaneous liver biopsy specimens, respectively.
  • Histology disclosed CD20 + CD5 - CD10 [corrected] - malignant large mononuclear B cells within the lumina of the blood vessels of the affected organs as well as sinusoids of the liver.
  • Significantly, the patient had a history of large B cell lymphoma affecting the eyelid 18 months prior to the angiotropic disease, suggesting a possible link between the more common types of non-Hodgkin's lymphoma and IVL.
  • [MeSH-major] Eyelid Neoplasms / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Lymphoma, B-Cell / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Alanine Transaminase / blood. Antigens, CD / analysis. Aspartate Aminotransferases / blood. B-Lymphocytes / chemistry. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Combined Modality Therapy. Drug Therapy, Combination. Humans. Immunohistochemistry. Male. Middle Aged. Radiotherapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathology 2002 Jun;34(3):301
  • (PMID = 11902454.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


20. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • A B-cell non-Hodgkin's lymphoma (NHL) was diagnosed from biopsies of the stomach and liver.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / complications. Lymphoma, B-Cell / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Iannitti T, Capone S, Gatti A, Capitani F, Cetta F, Palmieri B: Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy. Int J Nanomedicine; 2010;5:955-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1994, after an emergency hospital admission because of a sport-related thoracic trauma, a right inguinal lymph node biopsy demonstrated Hodgkin's lymphoma Stage IVB (scleronodular mixed cell subtype).
  • Although it was improved by chemotherapy, the disease suddenly relapsed, and a further lymph node biopsy was performed in 1998 confirming the same diagnosis.
  • Despite further treatment, the patient died of septic shock in 2004, at the age of 38 years.
  • Retrospective analysis of the various specimens showed intracellular heavy metal nanoparticles within lymph node, bone marrow, and liver samples by field emission gun environmental scanning electron microscopy and energy dispersive spectroscopy.
  • Heavy metals from environmental pollution may accumulate in sites far from the entry route and, in genetically conditioned individuals with tissue specificity, may act as cofactors for chronic inflammation or even malignant transformation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):154-65 [19371627.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Environ Health Perspect. 2009 May;117(5):A190 [19478977.001]
  • [Cites] Environ Health Perspect. 2009 Aug;117(8):A340; author reply A340-1 [19672380.001]
  • [Cites] Dtsch Med Wochenschr. 2009 Sep;134(39):1944-8 [19760557.001]
  • [Cites] Inhal Toxicol. 2009 Nov;21(13):1099-107 [19814607.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:491-6 [20008234.001]
  • [Cites] Environ Mol Mutagen. 2010 Mar;51(2):89-111 [19708067.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6400-5 [20308568.001]
  • [Cites] Environ Health Perspect. 2010 Jun;118(6):A240 [20515720.001]
  • [Cites] Chem Biol Interact. 2010 Nov 5;188(2):276-88 [20430016.001]
  • [Cites] Eur Spine J. 2007 Jul;16(7):1055-61 [17256156.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36207-12 [10593907.001]
  • [Cites] Biol Trace Elem Res. 2001 Nov;83(2):133-8 [11762530.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):61-4 [11748456.001]
  • [Cites] J Bone Joint Surg Br. 2003 Aug;85(6):913-7 [12931818.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):3-36 [14643411.001]
  • [Cites] Toxicology. 2004 Oct 1;202(3):249-69 [15337587.001]
  • [Cites] Sci Total Environ. 1985 Apr;42(3):237-43 [4001919.001]
  • [Cites] Int J Hematol. 1996 Oct;64(3-4):257-62 [8923788.001]
  • [Cites] Postepy Hig Med Dosw. 1996;50(4):383-94 [9019747.001]
  • [Cites] J Bone Joint Surg Am. 1998 Feb;80(2):268-82 [9486734.001]
  • [Cites] J Bone Joint Surg Am. 1998 Oct;80(10):1447-58 [9801213.001]
  • [Cites] Recent Results Cancer Res. 1998;154:3-21 [10026990.001]
  • [Cites] Med Pr. 2005;56(3):249-55 [16218139.001]
  • [Cites] Environ Mol Mutagen. 2007 Jan;48(1):30-7 [17163505.001]
  • [Cites] Can Nurse. 2007 Jan;103(1):22-6 [17269580.001]
  • [Cites] Environ Health Perspect. 2007 Sep;115(9):1264-70 [17805414.001]
  • [Cites] Mutat Res. 2008 Jun 30;654(1):45-51 [18541454.001]
  • [Cites] Arch Toxicol. 2008 Aug;82(8):493-512 [18496671.001]
  • [Cites] Crit Rev Toxicol. 2008;38(8):645-74 [18720105.001]
  • [ErratumIn] Int J Nanomedicine. 2011;6:239. Capitani, Frederico [corrected to Capitani, Federico]
  • (PMID = 21187947.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Metals, Heavy
  • [Other-IDs] NLM/ PMC3010157
  • [Keywords] NOTNLM ; Hodgkin’s lymphoma / environmental exposure / heavy metals / host–particle interactions / nanoparticles / nanotoxicity
  •  go-up   go-down


22. Brisse H, Servois V, Bouche B, Avni F, Petit P, Thibault F, Zucker JM, Devalck C, Neuenschwander S: Hepatic regenerating nodules: a mimic of recurrent cancer in children. Pediatr Radiol; 2000 Jun;30(6):386-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pseudometastatic lesions of the liver may be discovered incidentally in children previously treated for malignant tumour.
  • MATERIALS AND METHODS: Nine children, 2-12 years' old at the time of diagnosis, are described in this retrospective multicentre report.
  • The primary tumours were: nephroblastoma (n = 2), neuroblastoma (n = 2), Ewing's tumour/PNET (n = 2), non-Hodgkin's lymphoma (n = 1), and osteosarcoma (n = 2), treated by surgery (8/9), chemotherapy (9/9), intensive chemotherapy and bone-marrow transplantation (5/9), and radiotherapy (7/9).
  • Three children suffered veno-occlusive disease (VOD) during treatment.
  • RESULTS: Lesions were discovered 15 months to 16 years after completing treatment.
  • CT was the most sensitive modality for diagnosis.
  • CONCLUSION: Pseudometastatic hypervascular hepatic nodules can appear after treatment of a malignant tumour in children.
  • The hypothesis of benign regenerative lesions secondary to treatment and/or VOD is considered.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Liver Regeneration. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10876822.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] GERMANY
  •  go-up   go-down


23. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science; 2008 Aug 15;321(5891):974-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous attempts have shown the potential of T cells in immunotherapy of cancer.
  • Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of target cells in blood.
  • Blinatumomab also led to clearance of tumor cells from bone marrow and liver.
  • T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
  • [MeSH-major] Antibodies, Bispecific / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] B-Lymphocytes / immunology. Humans. Immunologic Memory. Immunophenotyping. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphocyte Count. Recurrence. T-Lymphocytes / immunology


24. Kusminsky G, Foncuberta MC, Aversa L, Drelichman G, Freigeiro D, Burgos R, Irrazabal C, Gonzalez G, Dictar M, Niborski R, Kohan A, Sanchez Avalos JC: [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood]. Medicina (B Aires); 2000;60(2):179-87
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis were acute myeloid leukemia (AML) in 16 pts, acute lymphoblastic leukemia (ALL) in 15, chronic myeloid leukemia (CML) in first chronic phase in 12, aplastic anemia in 4, myelodysplasia in 3 and Hodgkin's disease, major thalasemia and Hunter's syndrome in one each.
  • Conditioning regimens were total body irradiation with 1200 cGy and cyclophosphamide 120 mg/kg in 38 pts, busulfan 16 mg/kg and cyclophosphamide 120 mg/kg in 10 pts, total lymphoid irradiation and cyclophosphamide in 3, 2 pts received other chemotherapy based conditionings.
  • Two pts had venoocclusive disease of the liver.
  • Mean time for aGVHD diagnosis was +23 (8-76).
  • Chronic GVHD was observed in 26.4% by day +240, only 2 pts developed severe cGVHD.
  • The present experience demonstrates an acceptable incidence for cGVHD; however, taking into account recent reports showing an increase of this complication, it seems reasonable not to perform this procedure for non-malignant diseases in which graft versus malignancy effect is not to be expected.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Graft vs Host Disease / diagnosis. Graft vs Host Disease / epidemiology. Humans. Incidence. Infant. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Time Factors. Tissue Donors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10962806.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] ARGENTINA
  •  go-up   go-down


25. Gatta A, Giannini C, Lampertico P, Pontisso P, Quarta S, Zignego AL, Atzeni F, Sarzi-Puttini P: Hepatotropic viruses: new insights in pathogenesis and treatment. Clin Exp Rheumatol; 2008 Jan-Feb;26(1 Suppl 48):S33-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatotropic viruses: new insights in pathogenesis and treatment.
  • Recent data evaluated whether HBV occult infection could co-operate with HCV infection in the pathogenesis of mixed cryoglobulinemia (MC) and lymphoma and/or whether it may be implicated in the pathogenesis of MC and malignant diseases -B-cell non-Hodgkin's lymphoma (NHL) also independently from HCV.
  • The treatment of chronic HBeAg-negative hepatitis B is intended to ensure the long-term suppression of HBV replication with the aim of halting the progression of liver damage and preventing the development of liver-related complications.
  • This can be done by means of short-term "curative" treatment or long-term "suppressive" therapy.
  • As none of the currently available drugs alone suppresses viral replication (HBV DNA <200 copies/ml) for five years in all patients, some require a rescue therapy based on the addition of a non-cross-resistant drug, which should be given as early as possible ("on demand" combination therapy).
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B virus / drug effects. Hepatitis B, Chronic / drug therapy. Hepatitis B, Chronic / virology
  • [MeSH-minor] Hepacivirus / drug effects. Hepacivirus / immunology. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / immunology. Hepatitis C, Chronic / virology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570752.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 48
  •  go-up   go-down


26. Liebman H: Other immune thrombocytopenias. Semin Hematol; 2007 Oct;44(4 Suppl 5):S24-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immune thrombocytopenic purpura (ITP) can be classified as primary (known also as idiopathic thrombocytopenic purpura) or as secondary to an underlying condition such as a malignant or nonmalignant disorder.
  • Commonly occurring conditions associated with secondary ITP include lymphoproliferative disorders (chronic lymphocytic leukemia [CLL], Hodgkin's disease and non-Hodgkin's lymphomas), autoimmune collagen vascular diseases (systemic lupus erythematosus [SLE], thyroid disease, antiphospholipid syndrome [APS]), and chronic infections (human immunodeficiency virus [HIV], Helicobacter pylori, hepatitis C virus [HCV]).
  • Drug-induced thrombocytopenias are uncommon and generally resolve quickly upon drug discontinuation, but are often attributed to other causes.
  • In patients with HCV-related cirrhotic liver disease, splenic sequestration secondary to portal hypertension and decreased production of thrombopoietin may further contribute to development of thrombocytopenia.
  • The current treatment paradigm for secondary ITP varies according to the underlying condition.
  • Standard treatments for primary ITP (corticosteroids, IVIG, anti-D, splenectomy) are often successful in secondary ITP.
  • In cases of ITP with H pylori and HCV infection, treatment should focus on the underlying disorder.
  • [MeSH-major] Blood Platelets / immunology. Thrombocytopenia / diagnosis. Thrombocytopenia / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / immunology. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / drug therapy. Antiphospholipid Syndrome / immunology. Diagnosis, Differential. Female. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / immunology. Hepatitis C / complications. Hepatitis C / drug therapy. Hepatitis C / immunology. Humans. Leukemia / complications. Leukemia / drug therapy. Leukemia / immunology. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Lupus Erythematosus, Systemic / immunology. Lymphoma / complications. Lymphoma / immunology. Lymphoma / therapy. Male. Platelet Count. Thyroid Diseases / complications. Thyroid Diseases / immunology. Thyroid Diseases / therapy

  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096469.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 152
  •  go-up   go-down






Advertisement